1. Sharma A, Kondo M, Iwahashi C, Parachuri N, Kumar N, Bandello F, et al. Approved biosimilar ranibizumab—a global update. Eye (Lond). 2023;37:200–2.
2. Chong Kun Dang Pharmaceutical Corp.: https://www.globaldata.com/company-profile/chong-kun-dang-pharmaceutical-corp/. Accessed September 2023.
3. Ximluci (ranibizumab). https://www.ema.europa.eu/en/medicines/human/EPAR/ximluci. Accessed September 2023.
4. In the Lucentis biosimilars wars, there are no winners so far https://www.retina-specialist.com/article/in-the-lucentis-biosimilars-wars-there-are-no-winners-so-far#:~:text=According%20to%20SGI’s%20data%2C%20Eylea,percent%20filling%20out%20the%20market.&text=Other%20factors%20are%20impacting%20biosimilar%20uptake%20in%20retina%20Ms. Accessed September 2023.
5. Biocon Biologics Receives European Commission Approval for YESAFILI®, Biosimilar Aflibercept. https://www.biocon.com/biocon-biologics-receives-european-commission-approval-for-yesafili-biosimilar-aflibercept/. Accessed September 2023.